Bioventus, BCBS of Michigan partner in knee OA initiative — 3 things to know

Alan Condon -   Print  |

Bioventus is partnering with Blue Cross Blue Shield of Michigan to provide its knee osteoarthritis treatments to Medicare Advantage and Commercial patients, beginning Jan. 1, 2020.

Three things to know:

1. The arrangement includes Bioventus' Durolane, Gelsyn-3 and Supartz FX hyaluronic acid-based treatments for knee OA.

2. Durolane is a single-injection, Gelsyn-3 is a three-injection, and Supartz FX is a five-injection joint fluid treatment.

3. Earlier this year Bioventus signed a nationwide contract with UnitedHealthcare to make Durolane and Gelsyn-3 available to employer and individual commercial plans, starting Oct. 1.

More articles on biologics:
Johns Hopkins, Carrum partnership grows to spine surgery
New York spine surgeon sentenced to probation, house arrest — 4 insights
11 PE transactions in orthopedics in 2019

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers